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C ardio-oncology, a new clinical discipline focused on thecardiovascular care of cancer patients, represents a new
avenue for interdisciplinary collaboration between clinical
oncologists and cardiologists as well as between basic
scientists and clinical investigators.1 Many of these collabo-
rations have been driven by the emergence of novel targeted
therapies that have revolutionized cancer treatment but also
have the potential for cardiovascular toxicity.
The recent history of treatment for HER2 positive breast
cancer is an early example of how unanticipated cardiotoxicity
has led to collaborative efforts to address the problem. HER2, a
proto-oncogene encoding the HER2 receptor tyrosine kinase,
is ampliﬁed in >20% of patients with breast cancer, resulting in
HER2 receptor overexpression and an aggressive phenotype
associated with high metastatic potential and short survival.
The development of trastuzumab (Herceptin), a humanized
monoclonal antibody targeting HER2, over the past 15 years
has led to signiﬁcant improvements in the survival of patients
with HER2-positive breast cancer. A pivotal study by Slamon
et al demonstrated a clear beneﬁt of trastuzumab in meta-
static HER2+ breast cancer. However, there was an alarming
rate of cardiotoxicity with 27% of patients who received
trastuzumab concurrently with traditional chemotherapy
(doxorubicin, cyclophosphamide) developing either symptom-
atic heart failure or asymptomatic cardiac dysfunction.2 As a
result of these data, initial regulatory approval of trastuzumab
for metastatic breast cancer was accompanied by caveats with
respect to cardiac safety. Several requirements were instituted
for therapy in practice. First, all patients would undergo
frequent periodic monitoring of cardiac function with determi-
nation of left ventricular ejection fraction (EF) during the
course of trastuzumab treatment. Second, trastuzumab would
be administered sequentially after treatment with anthracy-
cline-based chemotherapy under the assumption that syner-
gistic toxicity could result if the 2 agents were given
concomitantly. These stipulations were not only applied to
patient care but also to subsequent clinical trials involving
trastuzumab, especially as this agent was being tested in the
adjuvant setting, to increase the chance of disease-free
survival. In the oncology community, these initial observations
with cardiotoxicity also led to a debate regarding the added
value of anthracyclines for patients with curable, early-stage
HER2 positive breast cancer being treated with trastuzumab.3
Perhaps as a result of close cardiac monitoring, subse-
quent clinical trials of trastuzumab in the adjuvant setting
have demonstrated a lower incidence of cardiotoxicity,
typically deﬁned as either symptomatic congestive heart
failure (CHF) or asymptomatic decline in left ventricular
systolic function (cardiomyopathy). In large, randomized
clinical trials, the incidence of symptomatic CHF ranged from
0.6% to 4.1% while the incidence of cardiomyopathy is higher
at 3% to 19%.4–6 The differences in the reported incidence
may be related to several factors including differences in
treatment regimens, differences in deﬁnitions of cardiomyop-
athy, and variation in the imaging modalities used to assess
EF. Despite these sources of heterogeneity, it is clear that
trastuzumab is associated with a small increased risk of
clinical congestive heart failure and a larger increased risk of
cardiomyopathy, especially on the background of anthracy-
cline therapy. However, these risks are juxtaposed against the
consistent ﬁnding in clinical trials that trastuzumab signiﬁ-
cantly decreases the risk of cancer recurrence and increases
survival in women with HER2-positive disease.
An important, unanswered question is the clinical signif-
icance of the cardiotoxicity associated with HER2-targeted
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therapies. In clinical trials involving trastuzumab, the majority
of patients who developed heart failure or cardiomyopathy
improved clinically, and most experienced an improvement in
EF although approximately one-third of patients had some
degree of persistent LV systolic dysfunction.4,6,7 In two trials
testing trastuzumab in the adjuvant setting, there were no
cardiac deaths in the trastuzumab arms at a median follow-up
of 3.6 and 5.4 years, respectively.4,8 In addition, new-onset
cardiomyopathy can interrupt and inﬂuence the course of
cancer therapy. In clinical trials, 2% to 8% of HER2-positive
breast cancer patients were not candidates for trastuzumab
due to LV dysfunction or cardiac symptoms after completing
an anthracycline-containing regimen.4,7 Similarly, the devel-
opment of cardiac events, many of them asymptomatic,
during treatment with trastuzumab can lead to interruption or
cessation of treatment in up to 16% of women with a proven
survival beneﬁt.6,7
Deﬁning the exact short-term and long-term consequences
of trastuzumab-associated cardiomyopathy will be important
as clinicians are forced to weigh the risks versus beneﬁts of
trastuzumab therapy in the breast cancer population. More-
over, accurate risk prediction tools are needed to assist
clinicians in identifying patients at high risk of cardiotoxicity.
Answering these questions in the context of a “real world”
population is essential given that most oncology clinical trials
enroll younger patients with no history of cardiovascular
disease. In practice, over 40% of breast cancer patients are
>65 years of age, many of whom carry the burden of
traditional cardiovascular risk factors or have a history of
cardiovascular disease.9
In this issue of JAHA, Ezaz et al provide a risk prediction
model for heart failure and cardiomyopathy after adjuvant
trastuzumab therapy for breast cancer.10 The authors build on
their previous work using the Surveillance, Epidemiology, and
End Results (SEER) Medicare-linked database where they
identiﬁed 45 537 women who were 67 to 94 years of age
(mean age 76) with early-stage breast cancer. The adjusted 3-
year incidence of heart failure or cardiomyopathy was as high
as 42% for patients receiving anthracycline and trastuzumab,
32% for patients receiving trastuzumab alone, compared to
18% with no adjuvant therapy.9 There are obvious limitations
with such a retrospective approach, most of which are
acknowledged by the authors. Outcomes data were based on
administrative codes rather than a rigorous adjudication of
events, which limits the discrimination between symptomatic
and asymptomatic systolic dysfunction. The lack of data on
ejection fraction (EF) also limits the distinction between
systolic and diastolic heart failure, which may be important in
an older population. The degree of surveillance for asymp-
tomatic LV dysfunction was also not available given the nature
of the dataset. The strength of this type of registry analysis is
its large sample size and the fact that it is embedded within a
“real world” population. Combined with the work of others,
these data highlight a clear signal of increased cardiotoxicity
in an older population with rates signiﬁcantly higher than
those reported in clinical trials.11 The long-term prognosis of
these patients remains unknown.
The current paper by Ezaz et al represents an important
contribution to the understanding of risk factors for the
development of heart failure or cardiomyopathy in this
population. Using a subset of patients from the SEER
Medicare database, the authors developed a clinical risk
score based on 7 factors: age, adjuvant chemotherapy,
coronary artery disease, atrial ﬁbrillation or ﬂutter, diabetes,
hypertension, and renal failure. In a split sample design, the
authors developed the risk score in half the cohort and then
demonstrated internal validity with the other half. Using this
risk score allowed stratiﬁcation of patients into low-, medium-,
and high-risk groups. Validating this risk score in other
cohorts or registries will be critical for demonstrating its
generalizability. Nevertheless, the ﬁnding that pre-existing
cardiovascular disease and the presence of traditional risk
factors incrementally increase the risk of trastuzumab-asso-
ciated heart failure is an important ﬁnding and contribution to
the ﬁeld. Although these main results are not surprising
(based on clinical experience and lessons from studying other
forms of heart failure), formally reporting these ﬁndings in the
cardio-oncology population is important for conﬁrming obser-
vations made in practice. All efforts to expand the evidence
base in cardio-oncology will not only guide future practice, but
will also help to inform the design of future clinical trials. This
is especially important because, at this time, patients with
HER2+ breast cancer are treated with combinations of HER2-
targeted therapies, which, in turn, may add to the risk of
cardiotoxicity.
Several groups have previously reported risk factors for
developing trastuzumab-associated cardiomyopathy based on
data from clinical trials testing the efﬁcacy of trastuzumab in
the adjuvant setting. In the Herceptin Adjuvant (HERA) trial,
higher cumulative dose of doxorubicin, lower screening EF,
and greater body mass index were associated with increased
risk of clinical heart failure or cardiomyopathy.6 There was a
nonsigniﬁcant trend towards higher risk with hypertension,
smoking, and diabetes. Notably, this analysis involved a small
number of patients with these risk factors, and the mean age
of patients was 49 years. Similarly in another trial (NSABP-
31), age and EF were the only predictors of cardiotoxicity
while the prevalence of co-morbidities was also relatively low
compared to that in the current study.7
The current study should lead to further attempts by the
cardio-oncology community to improve cardiac risk stratiﬁca-
tion in patients with breast cancer. An increasing number of
studies have indicated the utility of novel imaging parameters
(eg, myocardial strain by echocardiography) and serum
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biomarkers (eg, troponin) on top of clinical risk factors in the
prediction of cardiomyopathy in breast cancer patients prior
to the onset of a reduction in EF.12,13 Integrating clinical risk
factors with novel imaging and serum biomarkers may
ultimately provide the clinician with a comprehensive, robust
risk prediction tool for all ages. A personalized risk score
could inﬂuence a variety of decisions related to cancer
therapy, such as whether to treat with an anthracycline, how
frequently to conduct cardiac surveillance, and in which
patients to initiate cardioprotective strategies (eg, beta
blockers, ACE inhibitors) while continuing trastuzumab ther-
apy (Figure). In an era of limited economic resources, such a
risk tool may also have a high enough negative predictive
value to identify a truly low-risk population for whom no
further intervention or surveillance is necessary. A carefully
constructed comparative effectiveness study designed to
capture both cardiovascular and oncologic outcomes would
be necessary to validate such a tool. The current work by Ezaz
et al is an important initial step towards a more patient-
centered approach in the assessment of cardiac risk during
breast cancer therapy.
Establishing risk prediction models for heart failure and
cardiomyopathy becomes even more important when one
considers the evolving landscape of treatment options for
HER2 positive breast cancer. HER2 directed therapy now
includes a diverse class of therapies including small molecular
tyrosine kinase inhibitors targeting HER2 (such as lapatinib,
afatinib, neratinib) and HER2 receptor dimerization inhibitors
(such as pertuzumab). In addition, trastuzumab has been
covalently linked to cytotoxic agents allowing more effective
tumor cell targeting such as in the case of Trastuzumab
emtansine (TDM-1), which was recently approved for treat-
ment of HER2+ metastatic breast cancer. Increasingly, these
HER2-targeted therapies are used in combination for the
treatment of breast cancer, potentially increasing the risk of
cardiotoxicity.14,15 HER2 signaling promotes breast cancer
proliferation though the RAS-MAPK pathway and inhibits cell
death through the phosphatidylinositol 30-kinase-AKT-mam-
malian target of rapamycin (mTOR) pathway. Inhibitors
targeting these downstream pathways are being developed
to both more potently inhibit HER2 signaling and/or develop
ways of addressing resistance to trastuzumab.16 At the
present time, the cardiac implications of these novel HER2-
targeted therapies are unknown.
The evolving narrative on cardiomyopathy in breast cancer
patients treated with trastuzumab highlights the importance
of a continued, close collaboration between oncologists and
cardiologists. Further research into the mechanisms, risk
factors, optimal methods of detection, and ultimately strat-
egies for prevention will help to achieve the goal of optimizing
both the cardiovascular and oncologic health in all of our
patients.
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Figure. Proposed integrated cardiac risk assessment for
patients undergoing breast cancer treatment.
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